Vortrag im Rahmen des Reutlinger Update Innere Medizin 2014 - 28. & 29. November 2014. Eine jährliche Fortbildungsveranstaltung der Bezirksärztekammer Südwürttemberg, der Kreisärzteschaft Reutlingen und der Kreiskliniken Reutlingen GmbH für Ärztinnen und Ärzte.
3. High risk: multiple adenomas and
adenomas with a villous component or
high-grade dysplasia
Long-Term Colorectal-Cancer Mortality after
Adenoma Removal
Magnus Løberg et al., NEJM 2014
4. 50-74 y; Screening interval 4 years
Measurement of prostate-specific antigen (PSA) in serum, with
a cutoff of 3·0 ng/mL or more, was the main screening test and
indication for biopsy (an ancillary test was used for men with
PSA 3·0–3·9ng/mL).
Sextant biopsies were initially recommended for screen-
positive men
Screening and prostate cancer mortality: results of the
European Randomised Study of Screening for Prostate
Cancer (ERSPC) at 13 years of follow-up
Fritz H Schröder, J et al., Lancet Oncology 2014
7. Oral rivaroxaban versus enoxaparin with vitamin K
antagonist for the treatment of symptomatic venous
thromboembolism in patients with cancer (EINSTEIN-DVT
and EINSTEIN-PE): a pooled subgroup analysis of two
randomised controlled trials
Martin H Prins, et al., Lancet Hematology 2014
Rivaroxaban (15 mg twice daily for 21 days,
followed by 20 mg once daily)
Standard therapy (enoxaparin 1·0 mg/kg twice
daily and warfarin or acenocoumarol)
10. Efficacy of Methylprednisolone on Pain, Fatigue, and Appetite
Loss in Patients With Advanced Cancer Using Opioids: A
Randomized, Placebo-Controlled, Double-Blind Trial
Ørnulf Paulsen, et al., JCO 2014
Methylprednisolone 32mg/Tag
14. ASCO (best of) 2012
Lancet Oncology 2013
2013 AIO Wissenschaftspreis der
Deutschen Krebsgesellschaft
Antiangiogenese über den Progress
hinaus beim kolorektalen Karzinom
15. Bevacizumab plus chemotherapy versus chemotherapy alone as
second-line treatment for patients with HER2-negative locally recurrent
or metastatic breast cancer after first-line treatment with bevacizumab
plus chemotherapy (TANIA): an open-label, randomised phase 3 trial
Gunter von Minckwitz, et al., Lancet Oncology 2014
32. Survival follow-up and ipilimumab retreatment of patients
with advanced melanoma who received ipilimumab in prior
phase II studies. C. Lebbé et al., Ann Oncol 2014.
33. Nivolumab in Previously Untreated
Melanoma without BRAF Mutation.
Caroline Robert et al., NEJM 2014.